![](https://www.diabetesnews.com/wp-content/uploads/2012/11/159749384-150x150.jpg)
Novo Nordisk’s new ultra long-acting insulin degludec is associated with a higher heart risk than other diabetes treatments, although the size of the risk is uncertain, U.S. regulators said on Tuesday.
Read more
Novo Nordisk’s new ultra long-acting insulin degludec is associated with a higher heart risk than other diabetes treatments, although the size of the risk is uncertain, U.S. regulators said on Tuesday.
Read more